MediWound Ltd. (MDWD) – What Are Investment Firms Thinking About This Stock?

Shares of MediWound Ltd. (NASDAQ:MDWD) have earned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $33.00.

Several research analysts have recently commented on MDWD shares. Wall Street Zen raised MediWound from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 26th. TD Cowen reaffirmed a “buy” rating on shares of MediWound in a research report on Thursday, September 24th. Weiss Ratings lowered MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. Alliance Global Partners reiterated a “buy” rating on shares of MediWound in a research note on Wednesday, September 16th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $30.00 target price (down from $32.00) on shares of MediWound in a report on Friday, August 14th.

Insider Buying and Selling at MediWound

In other news, COO Shmuel Hess sold 3,958 shares of the firm’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $12.92, for a total value of $51,137.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On MediWound

A hedge fund recently raised its stake in MediWound stock. Silverberg Bernstein Capital Management LLC grew its position in MediWound Ltd. (NASDAQ:MDWD) by 8.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 200,005 shares of the biopharmaceutical company’s stock after purchasing an additional 16,081 shares during the quarter. MediWound comprises approximately 1.8% of Silverberg Bernstein Capital Management LLC’s investment portfolio, making the stock its 16th biggest holding. Silverberg Bernstein Capital Management LLC owned about 1.56% of MediWound worth $3,222,000 at the end of the most recent quarter. 46.83% of the stock is owned by hedge funds and other institutional investors.

MediWound Stock Performance

NASDAQ MDWD opened at $12.21 on Friday. The company has a market cap of $156.92 million, a PE ratio of -6.78 and a beta of 0.09. The firm’s 50 day moving average price is $13.29 and its 200-day moving average price is $14.68. MediWound has a 52-week low of $11.87 and a 52-week high of $20.03.

MediWound (NASDAQ:MDWD) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%. The company had revenue of $3.09 million for the quarter, compared to analysts’ expectations of $2.59 million. On average, analysts forecast that MediWound will post -2.37 earnings per share for the current fiscal year.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biotechnology company focused on developing and commercializing innovative therapies for complex wounds. The company’s products are designed to remove damaged tissue, support wound healing and address unmet needs in burn care and chronic wounds.

MediWound’s lead commercial product is NexoBrid, a topical bromelain-based enzymatic treatment used to remove eschar—the dead tissue that can form after severe thermal burns. NexoBrid has received regulatory approvals in multiple markets, including the United States, the European Union and Israel, and is marketed for use in the treatment of deep partial-thickness and full-thickness burns.

The company is also developing EscharEx, an investigational topical treatment intended to enzymatically debride chronic wounds, including venous leg ulcers.